Natera, Inc. is a global molecular diagnostics company headquartered in San Carlos, California. Founded in 2004 by Matthew Rabinowitz and Jonathan Sheena, the company specializes in developing and commercializing non-invasive genetic testing technologies. Natera’s platform leverages proprietary DNA analysis and bioinformatics to deliver insights across reproductive health, oncology and organ transplantation without the need for invasive procedures.
In the reproductive health arena, Natera’s flagship product is the Panorama™ non-invasive prenatal test (NIPT), which screens for fetal chromosomal abnormalities as early as ten weeks into pregnancy. The company also offers Horizon™ carrier screening for inherited single-gene disorders, enabling prospective parents to understand their genetic risk prior to conception or early in gestation.
Within oncology, Natera markets Signatera™, a personalized circulating tumor DNA (ctDNA) assay designed to detect minimal residual disease (MRD) and monitor treatment response in a variety of cancers. For organ transplantation, the Prospera™ assay quantifies donor-derived cell-free DNA to assess the risk of graft rejection. These tests aim to provide clinicians with actionable data to guide patient management and therapeutic decisions.
Natera went public on the Nasdaq stock exchange in December 2015 and has since expanded its testing services into Europe, Asia-Pacific and Latin America. Its centralized laboratories and global partnerships support thousands of healthcare providers and research institutions. The company continues to invest in R&D to enhance its genomics platform under the leadership of founder and Chief Scientific Officer Matthew Rabinowitz and an experienced executive team.